- Home
- ATXS vs WEYS Comparison
ATXS vs WEYS Comparison
Compare ATXS & WEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- WEYS
- Stock Information
- Founded
- ATXS 2008
- WEYS 1906
- Country
- ATXS United States
- WEYS United States
- Employees
- ATXS N/A
- WEYS N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- WEYS Apparel
- Sector
- ATXS Health Care
- WEYS Consumer Staples
- Exchange
- ATXS Nasdaq
- WEYS Nasdaq
- Market Cap
- ATXS 401.2M
- WEYS 341.7M
- IPO Year
- ATXS 2015
- WEYS N/A
- Fundamental
- Price
- ATXS $5.34
- WEYS $30.48
- Analyst Decision
- ATXS Strong Buy
- WEYS
- Analyst Count
- ATXS 5
- WEYS 0
- Target Price
- ATXS $26.60
- WEYS N/A
- AVG Volume (30 Days)
- ATXS 276.5K
- WEYS 14.1K
- Earning Date
- ATXS 03-11-2025
- WEYS 03-04-2025
- Dividend Yield
- ATXS N/A
- WEYS 9.77%
- EPS Growth
- ATXS N/A
- WEYS N/A
- EPS
- ATXS N/A
- WEYS 3.16
- Revenue
- ATXS N/A
- WEYS $290,290,000.00
- Revenue This Year
- ATXS N/A
- WEYS N/A
- Revenue Next Year
- ATXS N/A
- WEYS N/A
- P/E Ratio
- ATXS N/A
- WEYS $9.59
- Revenue Growth
- ATXS N/A
- WEYS N/A
- 52 Week Low
- ATXS $5.29
- WEYS $27.05
- 52 Week High
- ATXS $14.04
- WEYS $41.05
- Technical
- Relative Strength Index (RSI)
- ATXS 28.85
- WEYS 43.42
- Support Level
- ATXS $5.89
- WEYS $29.64
- Resistance Level
- ATXS $6.52
- WEYS $30.92
- Average True Range (ATR)
- ATXS 0.40
- WEYS 0.88
- MACD
- ATXS -0.06
- WEYS 0.26
- Stochastic Oscillator
- ATXS 2.50
- WEYS 74.14
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About WEYS Weyco Group Inc.
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale and the North American retail segment. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.